Israeli-based RedHill Biopharma has signed a co-promotion agreement with Canadian-based Concordia International’s subsidiary to acquire certain US promotion rights for the prescription oral drug Donnatal that is used with other drugs to treat irritable bowel syndrome (IBS).

IBS is a chronic multifactorial disorder characterised by recurrent abdominal pain or discomfort associated with altered bowel function.

As per the agreement terms, RedHill will be responsible for certain promotional activities related to the drug, while Concordia will take responsbility for its manufacturing and supply in all territories.

RedHill CEO Dror Ben-Asher said: “With a core US commercial team in place, we plan to initiate promotional activities in the US in the coming months with a specialty gastrointestinal sales force.

“RedHill’s strategic transition into a revenue-generating, gastrointestinal-focused, specialty pharmaceutical company with commercial presence in the US, is planned to support potential future commercialisation of our Phase III-stage potential blockbusters Bekinda for gastroenteritis and other GI indications, RHB-105 for H. pylori infection and RHB-104 for Crohn’s disease, if approved by FDA.”

"This agreement is a cost-effective approach to promoting Donnatal in a manner consistent with our long-term strategic focus on operational excellence."

Based on an agreed upon split, RedHill and Concordia will share the revenues generated from the promotion of the drug.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The agreement with Concordia is initially for a period of three years.

Concordia CEO Allan Oberman said: “This agreement is a cost-effective approach to promoting Donnatal in a manner consistent with our long-term strategic focus on operational excellence.

“We look forward to partnering with them to market Donnatal to more key prescribers who we believe can help raise the product’s profile and potentially allow us to reach more patients in the US.”

Donnatal relaxes the muscles in the stomach and intestines and acts on the brain to produce a calming effect and slows the natural movements of the gut.

It is available in two formulations: immediate release Donnatal Tablets, and immediate release Donnatal Elixir, a fast acting liquid.